Tagged Articles

attorneys 329 articles

Melanoma drug proves superior in clinical trials


Merck & Co.’s cancer drug Keytruda (pembrolizumab) was superior in treating patients of advanced melanoma in phase III clinical trials compared to Bristol-Myers Squibb Co.’s Yervoy (ipilimumab). Keytruda is in a class of cancer drugs known as PD-1 inhibitors. It is currently approved for the treatment of unresectable or metastatic melanoma, and in patients whose disease has progressed after the use of the standard treatment, Yervoy. The positive results of the latest trial of Keytruda is good news for the large number of patients worldwide with skin cancer. Melanoma is the deadliest form of skin cancer because it can be ... Read More

Lawsuit claims arsenic in wines is dangerously high

wine - arsenic

A class action lawsuit filed in behalf of California consumers claims that California wineries are producing wine contaminated with dangerously high levels of arsenic and failing to warn consumers about the potential risks of arsenic exposure. The lawsuit targets 28 wineries including Franzia, Sutter Home, Wine Cube, Cupcake, Beringer and Vendage, and involve mostly inexpensive white or blush varieties such as moscato, pinot grigio, and sauvignon blanc. Plaintiffs attorneys say 1,306 different types of wine were tested by BeverageGrades of Denver, and 83 showed dangerously elevated levels of inorganic arsenic in wines. The results were confirmed by two other labs. ... Read More

McNeil denied appeal in $10 million Children’s Motrin verdict


The Pennsylvania Supreme Court refused to hear an appeal by Johnson & Johnson unit McNeil-PPC Inc., of a $10 million verdict levied against the company by the family of a girl who suffered a serious allergic reaction and blindness after taking Children’s Motrin as prescribed for fever. McNeil had petitioned the state high court to hear the case after its bid for appeal was rejected by the Pennsylvania Superior Court panel last September. The panel supported the lower court’s decision in July, which found the consumer health care company failed to warn that its over-the-counter medicine could cause the serious ... Read More

Risperdal makers attempt to discredit former FDA chief in gynecomastia lawsuit


Johnson & Johnson attorneys attempted to discredit former Food and Drug Administration (FDA) chief who testified against the company in a lawsuit claiming its antipsychotic drug Risperdal causes adolescent boys to grow breasts. Former FDA Commissioner David Kessler testified in front of a Philadelphia jury last week in the gynocomastia lawsuit saying, “What (Johnson & Johnson and its subsidiary Janssen Pharmaceuticals) want to convey here, as you see in their own words, doesn’t match what the data show and, to me, that’s not telling the whole story, especially when you’re talking about adverse events that are significant. “The one thing you ... Read More

New lawsuit claims baby powder for personal hygiene caused ovarian cancer

baby powder contains talc

Johnson & Johnson faces a new lawsuit claiming the use of its talcum powder for feminine hygiene caused ovarian cancer. Judith Harlan claims she used the company’s baby powder regularly on her genitals for nearly 50 years, trusting the product’s label that it safe even for babies. In 2013, Judith was diagnosed with ovarian cancer, one of the most deadly forms of cancer among women. Judith learned that in 1971 the first study emerged showing a link between talcum powder and cancer. In 1982, another study showed that women who repeatedly used talcum powder on their genitals for personal hygiene were ... Read More

Judge allows new expert for plaintiffs in Risperdal gynecomastia lawsuit


A Philadelphia State judge rejected Johnson & Johnson subsidiary Janssen Pharmaceutical attorney’s claims that the company was prejudiced by a new expert witness for plaintiffs in a lawsuit alleging Janssen’s antipsychotic drug Risperdal caused a boy to grow large female breasts. The condition is known as gynocomastia. Defense attorneys argued that Janssen had been disadvantaged by the new expert’s testimony, which contained different opinions than those of a previous expert witness. The previous witness suddenly withdrew from the case after defense attorneys accused the doctor of failing to comply with state law when he examined the plaintiff in his home state ... Read More

Judge tells Janssen attorney to ‘play by rules’ in Risperdal gynecomastia lawsuit


A Pennsylvania State judge told an attorney for Johnson & Johnson subsidiary Janssen Pharmaceuticals that she had to “play by the rules to get a fair trial,” in a lawsuit alleging the company’s antipsychotic drug Risperdal caused a boy to grow large female breasts. “There are some rules of civil procedure in this state and therefore we’re going to follow them,” Philadelphia County Court of Common Pleas Judge Ramy Djerassi told the defense attorney when pointing out that Janssen biochemist Ivo Caers could not testify on pharmaceutical regulations in the United States. Caers could only speak to his own experience ... Read More

Judge slaps Takeda with additional damages in Actos bladder cancer lawsuit

Actos (pioglitazone) Type 2 diabetes medication

A Pennsylvania judge refused to overturn a $2 million verdict against Takeda Pharmaceuticals Inc. involving claims that its type 2 diabetes drug Actos caused bladder cancer, and slapped the drug company with nearly $100,000 in additional damages for the delay. Plaintiff Frances Wisniewski filed the lawsuit in Philadelphia Court of Common Pleas in July 2012 claiming she developed bladder cancer after taking Actos for seven years. In August 2011, the Food and Drug Administration (FDA) ordered Takeda to update the safety label of Actos to include warnings for bladder cancer risk in patients who used the drug for more than a ... Read More

Mass tort docket established for several Xarelto bleeding risk lawsuits


About 75 lawsuits against Bayer Healthcare Pharmaceuticals and Janssen Pharmaceuticals alleging major bleeding risks with the companies’ anticoagulant Xarelto have been moved into a mass tort docket by Philadelphia Court of Common Pleas Administrative Judge Kevin Dougherty and will be transferred to the court’s Complex Litigation Center. “The creation of a mass tort program benefits the Court system and the parties by eliminating duplicative discovery, inconsistent rulings and promoting the efficient prosecution and resolutions of similar cases,” said an attorney for the plaintiffs. “The defendants have strong ties to Pennsylvania making this an appropriate and convenient forum.” Xarelto is an ... Read More

Judge shoots down mistrial bid by Janssen in Risperdal gynecomastia lawsuit


A Pennsylvania state judge rejected a bid for a mistrial this week from Johnson & Johnson unit Janssen Pharmaceuticals in a lawsuit alleging the company’s antipsychotic drug Risperdal caused an adolescent boy to grow large female breasts. Attorneys for Janssen argued that a mistrial was warranted because plaintiff’s attorneys were trying to pass off an expert witness to testify about Risperdal side effects when that expert, a physician in Pennsylvania, was not licensed in Alabama, where the plaintiffs lived and where physician had examined the boy. The physician, Dr. David Goldstein, had opted to withdraw from the Risperdal gynecomastia lawsuit ... Read More